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Abstract
Diabetic nephropathy (DN) remains incurable and is the main cause of end-
stage renal disease. We approached the pathophysiology of DN with systems
biology, and a comprehensive profile of renal transcripts was obtained with
RNA-Seq in ZS (F1 hybrids of Zucker and spontaneously hypertensive heart
failure) rats, a model of diabetic nephropathy. We included sham-operated
lean control rats (LS), sham-operated diabetic (DS), and diabetic rats with
induced renal ischemia (DI). Diabetic nephropathy in DI was accelerated by
the single episode of renal ischemia. This progressive renal decline was associ-
ated with renal iron accumulation, although serum and urinary iron levels
were far lower in DI than in LS. Furthermore, obese/diabetic ZS rats have sev-
ere dyslipidemia, a condition that has been linked to hepatic iron overload.
Hence, we tested and found that the fatty acids oleic acid and palmitate stim-
ulated iron accumulation in renal tubular cells in vitro. Renal mRNAs encod-
ing several key proteins that promote iron accumulation were increased in DI.
Moreover, renal mRNAs encoding the antioxidant proteins superoxide dismu-
tase, catalase, and most of the glutathione synthetic system were suppressed,
which would magnify the prooxidant effects of renal iron loads. Substantial
renal iron loads occur in obese/diabetic rats. We propose that in diabetes,
specific renal gene activation is partly responsible for iron accumulation. This
state might be further aggravated by lipid-stimulated iron uptake. We suggest
that progressive renal iron overload may further advance renal injury in
obese/diabetic ZS rats.
Introduction
Diabetic nephropathy (DN) remains incurable and still is
the main cause for end-stage renal disease (ESRD) (U.S.
Renal Data System, 2013) (Kelly and Dominguez 2010).
The pathophysiology of DN is complex, and human stud-
ies are necessarily limited in their scope. It is for this rea-
son that animals have been used as surrogates to study
disease mechanisms. The ZS (F1 hybrids of Zucker and
spontaneously hypertensive heart failure) rat is a model
of obesity, diabetes, and dyslipidemia with progressive
nephropathy (Dominguez et al. 2007), and it is amenable
to systematic investigations not possible in humans
(Breyer et al. 2005; Temm and Dominguez 2007). As seen
in humans, episodes of acute renal injury (AKI) accelerate
renal inflammation, apoptosis, fibrosis, and failure in ZS
rats (Kelly et al. 2009). We recently showed that systems
biology, including deep sequencing with advanced bioin-
formatics, can be used to study the syndrome of acceler-
ated renal decline (Kelly et al. 2013). This approach
showed that obese, diabetic ZS rats with renal ischemia
exhibited general activation of the renal complement sys-
tem along with interacting proinflammatory gene net-
works (Kelly et al. 2015). The inciting mechanisms of
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renal C3 activation were likely ischemic and prooxidant,
as detailed in earlier work (Kelly et al. 2013, 2015). It is
also noteworthy that the source of the renal prooxidant
state in ischemia is in part derived from renal iron, as
shown in isolated kidneys (de Vries et al. 2006). There-
fore, we hypothesized that renal iron overload, observed
in diabetes (Rajpathak et al. 2009; Zheng et al. 2011),
may also be a component of diabetic nephropathy. We
found that rats with diabetes and renal ischemia had
higher renal iron loads, even while renal transcripts
encoding cellular iron efflux were upregulated.
Subjects and Methods
Animal
The three groups of rats included here, and their core
renal transcript networks, including inflammation, have
been reported elsewhere (Kelly et al. 2013, 2015) Lean
and obese, diabetic male ZS rats (Charles River, Wilming-
ton, MA) were acquired at 8 weeks of age and fed Purina
diet #5008. Their body weights were measured and sera
were analyzed for creatinine, iron, and total iron binding
capacity (TIBC), and urine was analyzed for iron by the
clinical laboratory of the Indianapolis VA Hospital. Urine
protein was measured as previously described (Kelly et al.
2013). One group of obese/diabetic rats was subjected to
bilateral renal ischemia for 25 min at 10 weeks of age as
described (DI, or DMisch, n = 11) (Kelly et al. 2013).
The lean rats (LS, or Lean, n = 6) and a second obese/di-
abetic group (DS, or DMsham, n = 7) were subjected to
sham surgery. These rats were terminated at 28 weeks of
age, their kidneys removed, immediately frozen in liquid
nitrogen or fixed in 10% formalin and embedded in
paraffin, Figure 1. The frozen sections were used for mea-
surements of renal mRNA (below). There were four addi-
tional DI rats that were terminated at age 36 weeks and
are only included to demonstrate late and sustained renal
iron accumulation.
Histology
Kidney sections were stained with the Prussian blue pro-
tocol. The sections were deparaffinized and then
immersed in an acid solution of potassium ferrocyanide,
which reacts with renal ferric iron forming a bright blue
pigment: Prussian blue, or ferric ferrocyanide. The sec-
tions were then counterstained with nuclear fast red.
These stained renal sections were also used to measure
renal iron by quantitating the blue pixel density of ferric
ferrocyanide.
Immuno(western)blotting
Kidney cortices were homogenized in 25 mmol/L Tris,
pH 7.6, 150 mmol/L NaCl, 1% deoxycholate, 1% P-40,
0.1% SDS, and 29 Halt Protease Inhibitor Cocktail
(Thermo Scientific, Rockford, IL), and adjusted to a pro-
tein concentration of 2 mg/mL. The homogenates (20 lg)
were fractionated by electrophoresis through 16.5% poly-
acrylamide Tris-Tricine gels. After electrophoresis, pro-
teins were transferred to a nitrocellulose filter. Blocking
was carried out in 1% casein, 1X PBS for 1 h. Incubation
with primary antibody diluted in 1X PBS was for 1 h;
primary antibody was rabbit anti-ferritin, heavy chain
(1:1000) (Cat # ab81444; Abcam, Cambridge MA) and
mouse anti-actin (1:1000) (clone AC-40, Sigma-Aldrich,
St. Louis, MO). The filter was then washed in 1X PBS
and incubated with secondary antibodies diluted in 1X
PBS for 1 h. Secondary antibodies were IRDye 680 goat
anti-rabbit IgG (1:15,000) (Li-Cor Biosciences, Lincoln,
NB) and IRDye 800 CW goat anti-mouse IgG (1:20,000)
(Li-Cor Biosciences). After washing in 1X PBS, the filter
was scanned using an Odyssey Infrared Imaging System
(Li-Cor Biosciences) for visualization of immunoreactive
proteins. All steps were carried out at room temperature.
RNA-seq
Total kidney RNA isolation was performed as described
(Kelly et al. 2013). RNA, 3 lg, was fragmented with
RNAase III, cDNA libraries constructed with SOLiD
adaptors by reverse transcription (RT), and then
sequenced by strand-specific RNA-seq of short 50 bp
reads using the SOLiD 4 platform (Center for Medical
Genomics at Indiana University School of Medicine) as
described (Kelly et al. 2013). Sequence alignment to the
UCSC rat genome database was performed using BFAST
(Homer et al. 2009). Gene expression was calculated in
the form of Reads per Kilobase Exon Model per million
mapped reads (RPKM) (Mortazavi et al. 2008). To iden-
tify differentially expressed genes, we conducted Student’s
t-test on the logarithmically transformed RPKM values,
Figure 1. Experimental diagram. Left to right: ZS lean rats were
subjected to sham surgery at 10 weeks of age (LS, n = 6), whereas
obese/diabetic ZS rats were either sham-operated (DS, n = 7) or
subjected to renal ischemia for 25 min at 10 weeks of age (DI,
n = 11). Serum and urine samples were collected and rats
terminated at 28 weeks of age. There was a group of 4 DI rats
terminated at 36 weeks of age and are included only to
demonstrate sustained renal iron accumulation.
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comparing DI versus LS and DS versus LS. Network anal-
ysis was performed using Metacore Software (GeneGo,
Carlsbad, CA).
Cellular iron levels
A colorimetric ferrozine-based assay was used to quantify
iron in cultured cells (Riemer et al. 2004). Cell lysates ini-
tially mixed with equal volumes of 1.4 mol/L HCl and
4.5% KMn04, and then ferrozine iron-detection reagent
(6.5 mmol/L ferrozine, 6.5 mmol/L neocuproine,
2.5 mol/L ammonium acetate, and 1 mol/L ascorbic acid)
followed by a 30-min incubation and then absorbance
measured at 550 nm. The concentration was calculated by
comparing absorbance to a standard curve of FeCl3
standards.
Animal use statement
The experiments were conducted in conformity with the
“Guiding Principles for Research Involving Animals and
Human Beings.” The investigations were approved by the
Institutional Animal Care and Use Committee of Indiana
University School of Medicine.
Statistics
Results are expressed as means  1 standard error. Dif-
ferences in renal and metabolic parameters were deter-
mined by one-way analysis of variance (ANOVA) with
subsequent t-tests (when ANOVA indicated statistical sig-
nificance, GraphPad Prism, LaJolla, CA). Bonferroni cor-
rection was used for multiple comparisons. The null
hypothesis was rejected at P < 0.05.
Results and Discussion
The abnormal metabolic and renal phenotypes in the ZS
rats, subjects of this report, were described in detail in
earlier articles (Kelly et al. 2013, 2015). There were three
groups of ZS rats studied until 28 weeks of age: lean
sham-operated (LS), obese/diabetic sham-operated (DS),
and obese/diabetic subjected to a short period of bilateral
renal ischemia (DI). There was a separate group of DI
rats that was terminated at 36 weeks of age and included
to demonstrate progressive renal iron retention (Figs. 2,
3). The previously published data (Kelly et al. 2013, 2015)
showed that 28-week-old DS and DI rats were heavier
than the LS controls. The blood glucose levels were also
higher in DS and DI, respectively, when compared to LS
controls. Creatinine clearance rates were depressed in DS
and DI rats when compared to LS controls. Proteinuria,
normal in LS, was increased in DS and DI. Renal histol-
ogy showed cellular infiltrates that contained neutrophils
and mononuclear cells in DI and less in DS. There was
also more tubular damage plus interstitial and glomerular
fibrosis, particularly in the DI rats (vs. LS). The original
quantification and histology images have been shown in
earlier publications (Kelly et al. 2013, 2015). Here we
show the distribution of renal ferric ferrocyanide, or tis-
sue iron, in LS, DS, and DI at 28 weeks of age, and also
in DI at 36 weeks of age (Fig. 2).
Renal iron was found in some tubules of DS rats, but
mainly in renal tubules of DI rats at 28 weeks of age and
appeared more pronounced in DI rats at 36 weeks of age
(also see (Nakhoul et al. 2009). In addition, levels of fer-
ritin heavy chain were measured on western blots and
found to be proportional to renal iron deposits, consis-
tent with the finding that renal ferritin is a key source of
total ferritin (Cohen et al. 2010), and that ferritin is also
an important reservoir of iron (Fig. 3) (ten Kate et al.
1997).
Potential sources of accumulated renal iron in DS and
DI were investigated by measuring serum and urine iron
levels. We found that serum iron levels were severely
depressed in DI, and marginally reduced in DS when
compared to LS. We also measured total iron binding
capacity (TIBC); a clinical laboratory indicator of the
blood-carrying iron capacity, and an indirect marker of
transferrin levels. Total iron binding capacity was signifi-
cantly higher in DS and DI, and thus TIBC percent satu-
ration was lower in DS and DI, consistent with a state of
iron deficiency in DS and DI when compared to LS, a
result comparable to the human condition (ten Kate et al.
1997). Twenty-four hour urine iron levels were propor-
tional to serum iron levels, in that urinary iron levels in
DS and DI were also lower than in LS. In marked con-
trast, renal iron and ferritin levels were higher in DS and
DI. Accordingly, renal iron overload in diabetic rats does
not appear to be caused by higher renal iron-filtered
loads. We also found that there was a positive correlation
among serum creatinine and urinary protein with renal
iron and also with renal ferritin levels, (Fig. 3).
Tissue iron overload has been reported in humans with
the metabolic syndrome, and in particular it has been
strongly correlated with serum lipids, which are elevated
in obese/diabetic ZS rats, (Fig. 4) (Howard et al. 1991),
and also accumulate in kidneys of diabetic humans, mice
(Kang et al. 2015), and ZS rats (Dominguez et al. 2007).
Therefore, we tested whether the monounsaturated fatty
acid oleic acid, and the saturated fatty acid palmitate,
increased iron in cultured renal tubular cells from kidneys
of normal lean male ZS rats. After an initial 24 h of expo-
sure to the fatty acids, iron was added to the culture
media for 24 more hours in the continued presence of
the fatty acids. The two fatty acids caused substantial
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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increments in renal tubule iron accumulation, (Fig. 4).
Palmitate addition was more cytotoxic, as manifested by
tubular LDH release, wheras oleic acid or iron had lower
and comparable effects on tubular LDH release.
Renal transcripts encoding interacting proteins involved
in iron metabolism were assembled in a gene network
(Fig. 5). These transcripts were differentially expressed in
both conditions, DS and DI, when compared to control
A
B C D E
Figure 2. Renal ferritin on western blot and iron stain by Prussian Blue. Representative Western blot shows levels of the heavy chain of ferritin
in kidneys from diabetic/obese rats, postischemia (DI), and in kidneys of sham-operated obese/diabetic rats (DS). Ferritin was nearly
undetectable in kidneys from normal sham-operated lean rats (L), n = 4 for all, (A). Renal iron-stained blue (arrows). Iron was also found in
infiltrating leukocytes (arrowhead). Representative kidney sections from 28-week-old LS rats, Lean, (B); 28-week-old diabetic/obese, sham-
operated rats, DM/Sham, (C); 28-week-old, diabetic/obese ischemic rats, DM/isch, (D); and 36-week-old diabetic/obese ischemic rats, DM/isch,
(E) are presented, n = 4 for all.
Figure 3. Iron levels in blood, urine and kidney. The left panels show that serum iron levels (lg/100 mL) were lower in obese/diabetic ischemic
rats, n = 11 (speckled, DMisch, DI; P < 0.002) and in obese diabetic sham-operated rats, n = 7 (black/white dots, DMsham, or DS; P < 0.002)
than in lean sham-operated rats, n = 6 (gray, LEAN or LS). The clinical laboratory parameter total iron binding capacity (TIBC, lg/100 mL), a
surrogate measurement of transferrin, was higher in DMsham (P = 0.04) and DMisch (P < 0.004) than in LEAN. Hence, the percent saturation
of serum TIBC (% SAT) by iron was lower in DMsham and DMisch rats (P < 0.002 for both) than in LEAN rats. Urine iron levels (lg/24 h) were
also lower in obese/diabetic ischemic rats (DMisch; P < 0.05) and obese/diabetic sham-operated rats (DMsham) (NS) than in sham-operated
normal rats (LEAN). Levels of renal iron deposits (pixels of renal ferric ferrocyanide 9 200 high power filed) were higher in DMisch
(P = 2.9 9 106) and DMsham (P = 0.0005) than in LEAN rats. Renal heavy-chain ferritin levels measured by Western blot were higher in
DMisch (P < 0.05) and higher in DMsham (NS) than in LEAN. The ferritin heavy chain data were normalized to the corresponding actin band.
The right panels show a positive correlation for serum creatinine levels (mg/100 9 10) and urine protein mg/mg creatinine with renal iron
deposits (Top) and a positive correlation among serum creatinine and urine protein with renal ferritin levels (Bottom).
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transcripts (LS). The center piece of the network is accu-
mulated renal iron. The upper left corner of the network
shows increased levels of the iron-sensitive genes Bmp6
and its coreceptor Hfe2 (Hjv, Valenti et al. 2012; Gkou-
vatsos et al. 2014). Bmp6 is stimulated in iron overload
(Parrow and Fleming 2014), and it is shown interacting
positively with the renal Hamp (hepcidin) gene (McDon-
ald et al. 2014). This effect might be initiated by renal
inflammation and is thought to limit iron efflux from
cells, promoting intracellular iron retention (Babitt et al.
2006). These local interactions are ostensibly intrarenal,
whereas systemic hepcidin activation might have a differ-
ent and unrelated outcome (Parrow and Fleming 2014).
The activated renal Hfe (hemochromatosis) gene directly
regulates Hamp providing additional stimulatory input
(Babitt et al. 2007). Furthermore, suppressed renal epider-
mal growth factor (EGF) in DI/DS is less likely to restrain
activated hepcidin (Gulec et al. 2014). The network also
points to a positive interaction between the genes coding
for hepcidin and heme oxygenase 1 (Hmox1) (Latour
et al. 2014), which in turn is acted on by renal proapop-
totic p53 (Kartikasari et al. 2009) also stimulated in DI/
DS (Kelly et al. 2013). It is anticipated that renal iron
loads in DI/DS might be increased by the degradation of
renal heme, secondary to stimulated Hmox1 (Nam and
Sabapathy 2011). Another potential source of renal heme,
and iron, is from free hemoglobin, which, when com-
plexed with stimulated renal haptoglobin (Hp), is inter-
nalized via renal CD163 prior to lysosomal degradation
(Evstatiev and Gasche 2012). The figure alludes to the
potential role of two upregulated renal genes that facili-
tate iron transfer into tissues, the multi-copper oxidases
Cp (ceruloplasmin) and Heph (hephaestin) (Madsen
Figure 4. Serum lipids and cellular iron and toxicity in rat renal
tubular cells. Serum cholesterol and triglycerides were significantly
higher in DI (DMisch, n = 11), and DS (DMsham, n = 7) than in
normal rats (LEAN, n = 6; P < 0.05 for all) (Top). Rat renal tubular
cells were isolated from harvested rat renal tubules and cultured
until confluent. The cells were maintained with 0.2 mmol/L oleate
(dark gray), 0.2 mmol/L palmitate (cross hatch), or vehicle (light
gray) for 48 h, n = 4. Sodium ferric gluconate, 0, 25, 50, 75 and
100 lg/mL was then added during the last 24 h of culture with the
fatty acids. The two fatty acids increased the levels of cellular iron,
P < 0.04 (Middle; *). The incremental addition of iron was toxic to
renal tubular cells treated with vehicle (gray circle) and oleate (open
squares). The addition of iron to palmitate- (gray triangles) treated
cultures was more toxic than the other two groups, P < 0.007
(Bottom; *).
Figure 5. Renal iron metabolism gene pathways in diabetic
nephropathy. The network on the left side of iron accumulation
(Fe) contains upregulated (red), inhibited (blue, italics) (n = 4 for all
three groups, differences were significant, P < 0.05) or unchanged
transcripts (black). Green arrows show positive interactions. The
network placed upregulated renal Hamp (Hepcidin) in a key
position to promote iron overload, along with other upregulated
genes: Hfe2 (Hemochromatosis type 2), Hmox1/2 (Heme oxygenase
1 and 2), Hp (Haptoglobin), Cp (Ceruloplasmin), and Slc48a1
(Heme transporter 1). On the right side of Fe it is shown that renal
C3 component activation (Kelly et al. 2015) and Alox (Arachidonate
lipoxygenase) are activated by iron loads. C3 activation leads to cell
death via its derived C3b component (Kelly et al. 2015), and Alox is
involved in lipid peroxidation. Iron itself induces oxidant stress and
renal fibrosis via upregulated TGFbeta. Oxidant stress is
compounded by the inhibition of the renal genes encoding the
antioxidants SOD (superoxide dismutase), CAT (catalase), and of the
components of glutathione synthesis (embedded table).
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et al. 2001). The figure also includes upregulated Slc48a1
(heme responsive gene-1), which promotes iron overload
by delivering heme from the endosome to the cytosol
(Vashchenko and MacGillivray 2013). On the left side of
the figure, it is shown that DI/DS-induced suppression of
Cisd1, which encodes the mitochondrial protein Mitoneet
that potentially causes renal mitochondrial iron overload
as shown by others (Khan and Quigley 2013).
Figure 5 shows the elevated renal iron catalyzes the
lipid peroxidation reactions of lipoxygenases (Alox) (Per-
cival 1991; Kusminski et al. 2012), which can stimulate
renal fibrosis via generated lipid peroxides (Neau et al.
2014). Renal ischemia causes iron overload (Paller and
Hedlund 1988; Dominguez et al. 2008), and also acti-
vates renal C3 component (Kelly et al. 2015), with the
latter secondary to the former (Shah et al. 2011). Iron
can also catalyze the formation of reactive oxygen inter-
mediates, largely responsible for lipid peroxidation and
cell damage (Fig. 5) (de Vries et al. 2004). The renal
prooxidant stress in rats with DI (Dominguez et al.
2007) is further compounded by suppression of critical
antioxidant transcript systems, including catalase (down
1.7; P < 0.0002), superoxide dismutase (down 1.8;
P < 0.0002), and the enzymes that comprise the depleted
renal glutathione antioxidant system of obese/diabetic
rats (Neau et al. 2014). For example, in the embedded
table in Figure 5 is shown that renal genes encoding
critical components of the glutathione synthetic pathway
are generally depressed. It is noteworthy that Nfe2l2
(Nrf2), a major regulator of cell response to oxidative
stress is slightly increased, but this reaction seems to be
inadequate (Ishii and Mann 2014). Finally, renal decline
in DI is characterized by fibrosis (Dominguez et al.
2007), and reactive oxidant species can promote fibroge-
nesis in part by the action of TGF beta 1 on the upregu-
lated collagen genes 1, 3, and 4 (Liu and Gaston Pravia
2010) (Fig. 5).
Diabetic nephropathy is a complex and deadly compli-
cation, and its progression is mediated by a host of fac-
tors: proinflammatory, proapoptotic, antiproliferative,
and profibrotic (Kelly et al. 2013, 2015). We suggest that
renal damage might be further accelerated by iron over-
load, with significant prooxidant and proinflammatory
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